Frontiers in Pharmacology (Jun 2022)

Structural Insights Into the High Selectivity of the Anti-Diabetic Drug Mitiglinide

  • Mengmeng Wang,
  • Mengmeng Wang,
  • Mengmeng Wang,
  • Mengmeng Wang,
  • Jing-Xiang Wu,
  • Jing-Xiang Wu,
  • Lei Chen,
  • Lei Chen,
  • Lei Chen,
  • Lei Chen

DOI
https://doi.org/10.3389/fphar.2022.929684
Journal volume & issue
Vol. 13

Abstract

Read online

Mitiglinide is a highly selective fast-acting anti-diabetic drug that induces insulin secretion by inhibiting pancreatic KATP channels. However, how mitiglinide binds KATP channels remains unknown. Here, we show the cryo-EM structure of the SUR1 subunit complexed with mitiglinide. The structure reveals that mitiglinide binds inside the common insulin secretagogue-binding site of SUR1, which is surrounded by TM7, TM8, TM16, and TM17. Mitiglinide locks SUR1 in the NBD-separated inward-facing conformation. The detailed structural analysis of the mitiglinide-binding site uncovers the molecular basis of its high selectivity.

Keywords